IP Lawsuits Settled

Two lawsuits against prominent researcher Craig Thompson for allegedly failing to share intellectual property with his institution lead to a licensing agreement on cancer diagnostics.

By | September 5, 2012

Brian Turner" > Flickr, Brian Turner

In December 2011, the Leonard and Madlyn Abramson Family Cancer Research Institute, part of the Abramson Cancer Center of the University of Pennsylvania, filed a $1 billion lawsuit against its former head Craig Thompson, who at that time had moved on to become the president of Memorial Sloan-Kettering Cancer Center in New York City. Two months later, in February 2012, the University of Pennsylvania filed a second lawsuit.

Both lawsuits revolved around Thompson’s alleged secrecy regarding his involvement in the biotech company Agios Pharmaceuticals (a co-defendant in both suits) and business deals he was making based on his research on cancer cell metabolism.

The terms of the new settlement are “hazy,” ScienceInsider reported, but one known outcome is a licensing agreement between Agios and Penn involving diagnostics that measure metabolism of certain cancers.

“We are pleased to be collaborating with Penn and value the contributions of their scientists to this exciting field,” Agios Chief Executive Officer David Schenkein said in a press release. “We are excited to now focus on the most important task of all—transforming the lives of cancer patients.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech